Real-World Insights on Metabolic Dysfunction-Associated Steatohepatitis

Overview

This large US retrospective cohort study evaluated the clinical burden, disease progression, and prognostic utility of non-invasive tests (NITs) in patients with metabolic dysfunction-associated steatohepatitis (MASH). It highlighted the prevalence of comorbidities, medication use, mortality rates, and associations between FIB-4 scores and clinical outcomes.

Background

Metabolic dysfunction-associated steatohepatitis (MASH) is an inflammatory stage of metabolic dysfunction-associated steatotic liver disease (MASLD) linked to increased liver and cardiovascular mortality, especially in advanced fibrosis. Prior studies have focused mainly on cardiovascular comorbidities, with limited data on non-cardiovascular conditions and real-world prognostic tools. Non-invasive tests like FIB-4 are recommended for risk stratification but lack extensive validation in large real-world cohorts. This study addresses these gaps using a large US claims and electronic health record database.

Data Highlights

The study included adult patients diagnosed with MASH (ICD-10-CM: K75.81) from 2016 to 2021 with valid laboratory data to calculate FIB-4 scores. Patients were followed until death, liver transplant, loss to follow-up, or end of data availability in 2022. Comorbidities, medication use, and mortality outcomes were assessed. Patients were stratified by cirrhosis status and further by compensated or decompensated cirrhosis. Key laboratory parameters included AST, ALT, platelets, eGFR, LDL-C, triglycerides, and HbA1c. The study excluded patients with other liver diseases or confounding conditions to isolate MASH impact.

Key Findings

• MASH patients exhibited a high prevalence of metabolic comorbidities including overweight/obesity, diabetes, and cardiovascular disease.
• Non-cardiovascular comorbidities such as cancer, sleep apnea, and psychiatric disorders were also common but previously understudied.
• Mortality rates were elevated overall, with increased liver-related and cardiovascular mortality particularly in patients with cirrhosis.
• FIB-4 scores correlated with disease severity and mortality risk, supporting their utility in real-world risk stratification.
• Patients with decompensated cirrhosis had worse outcomes compared to those with compensated cirrhosis or no cirrhosis.
• Medication use patterns reflected management of metabolic and cardiovascular comorbidities, underscoring the need for comprehensive care.

Clinical Implications

Clinicians should recognize the broad clinical burden of MASH beyond cardiovascular disease, including non-cardiovascular comorbidities that impact patient outcomes. Non-invasive tests such as FIB-4 can effectively stratify risk and guide management decisions in routine practice. Early identification and monitoring of cirrhosis status are critical to optimize prognosis and tailor therapeutic interventions.

Conclusion

This large real-world study provides comprehensive insights into the clinical impact and progression of MASH, validating the prognostic value of non-invasive risk assessment tools. These findings support integrated approaches to managing the multifaceted comorbidity burden in MASH patients.

References

1. EASL Clinical Practice Guidelines 2023 -- Management of MASLD
2. AASLD Practice Guidance 2023 -- Diagnosis and Management of NASH
3. Optum Market Clarity Database Study 2022 -- Real-World MASH Outcomes